Reviva pharmaceuticals to host key opinion leader event on brilaroxazine (rp5063) in phase 3 clinical trials for schizophrenia

Virtual event on tuesday, may 2, 2023 at 11:00am et will feature key opinion leader (kol) larry ereshefsky, pharmd, bcpp, fccp, chief scientific officer, follow the molecule virtual event on tuesday, may 2, 2023 at 11:00am et will feature key opinion leader (kol) larry ereshefsky, pharmd, bcpp, fccp, chief scientific officer, follow the molecule
RVPH Ratings Summary
RVPH Quant Ranking